Khazaeli MB - Search Results

1

Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.

Safavy A, Georg GI, Vander Velde D, Raisch KP, Safavy K, Carpenter M, Wang W, Bonner JA, Khazaeli MB, Buchsbaum DJ. Safavy A, et al. Among authors: khazaeli mb. Bioconjug Chem. 2004 Nov-Dec;15(6):1264-74. doi: 10.1021/bc049868v. Bioconjug Chem. 2004. PMID: 15546192

2

Synthesis of N-[tris[2-[[N-(benzyloxy)amino]carbonyl]ethyl]methyl]succinamic acid, trisuccin. Hydroxamic acid derivatives as a new class of bifunctional chelating agents.

Safavy A, Buchsbaum DJ, Khazaeli MB. Safavy A, et al. Among authors: khazaeli mb. Bioconjug Chem. 1993 May-Jun;4(3):194-8. doi: 10.1021/bc00021a002. Bioconjug Chem. 1993. PMID: 8324008

3

Further studies on the protein conjugation of hydroxamic acid bifunctional chelating agents: group-specific conjugation at two different loci.

Safavy A, Khazaeli MB, Kirk M, Coward L, Buchsbaum DJ. Safavy A, et al. Among authors: khazaeli mb. Bioconjug Chem. 1999 Jan-Feb;10(1):18-23. doi: 10.1021/bc980045d. Bioconjug Chem. 1999. PMID: 9893959

4

Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes.

Safavy A, Raisch KP, Khazaeli MB, Buchsbaum DJ, Bonner JA. Safavy A, et al. Among authors: khazaeli mb. J Med Chem. 1999 Nov 18;42(23):4919-24. doi: 10.1021/jm990355x. J Med Chem. 1999. PMID: 10579854

5

Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.

Safavy A, Bonner JA, Waksal HW, Buchsbaum DJ, Gillespie GY, Khazaeli MB, Arani R, Chen DT, Carpenter M, Raisch KP. Safavy A, et al. Among authors: khazaeli mb. Bioconjug Chem. 2003 Mar-Apr;14(2):302-10. doi: 10.1021/bc020033z. Bioconjug Chem. 2003. PMID: 12643740

6

Synthesis of bombesin analogues for radiolabeling with rhenium-188.

Safavy A, Khazaeli MB, Qin H, Buchsbaum DJ. Safavy A, et al. Among authors: khazaeli mb. Cancer. 1997 Dec 15;80(12 Suppl):2354-9. doi: 10.1002/(sici)1097-0142(19971215)80:12+<2354::aid-cncr4>3.3.co;2-j. Cancer. 1997. PMID: 9406683

7

Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.

Safavy A, Khazaeli MB, Safavy K, Mayo MS, Buchsbaum DJ. Safavy A, et al. Among authors: khazaeli mb. Clin Cancer Res. 1999 Oct;5(10 Suppl):2994s-3000s. Clin Cancer Res. 1999. PMID: 10541333

8

Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.

Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL. Buchsbaum DJ, et al. Among authors: khazaeli mb. Clin Cancer Res. 1999 Oct;5(10 Suppl):3153s-3159s. Clin Cancer Res. 1999. PMID: 10541357

9

Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.

Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ. Rogers BE, et al. Among authors: khazaeli mb. Cancer Biother Radiopharm. 2005 Oct;20(5):502-13. doi: 10.1089/cbr.2005.20.502. Cancer Biother Radiopharm. 2005. PMID: 16248766 Free article.

10

Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.

Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF. Buchsbaum DJ, et al. Among authors: khazaeli mb. Clin Cancer Res. 2005 Nov 15;11(22):8180-5. doi: 10.1158/1078-0432.CCR-05-0607. Clin Cancer Res. 2005. PMID: 16299250

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

110 results

Search Page